MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

J. Haartsen; S. Agland; J. Baker; T. Burke; L. Rath; J. Lechner-Scott; B. Taylor; S. Vucic; M. Barnett; M. Slee; S. Hodgkinson; O. Skibina; A. Kermode; E. Butler; N. Shuey; C. Shaw; T. Hardy; I. L. Tan; H. Butzkueven; T. Spelman

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

J. Haartsen, S. Agland, J. Baker, T. Burke, L. Rath, J. Lechner-Scott, B. Taylor, S. Vucic, M. Barnett, M. Slee, S. Hodgkinson, O. Skibina, A. Kermode, E. Butler, N. Shuey, C. Shaw, T. Hardy, I. L. Tan, H. Butzkueven, T. Spelman

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	18-19
Journal	Multiple Sclerosis Journal
Volume	21
Publication status	Published - 2015

Cite this

Haartsen, J., Agland, S., Baker, J., Burke, T., Rath, L., Lechner-Scott, J., Taylor, B., Vucic, S., Barnett, M., Slee, M., Hodgkinson, S., Skibina, O., Kermode, A., Butler, E., Shuey, N., Shaw, C., Hardy, T., Tan, I. L., Butzkueven, H., & Spelman, T. (2015). MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events. Multiple Sclerosis Journal, 21, 18-19.

@article{91e859df2a81461e922a02eb3d2618d2,

title = "MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events",

author = "J. Haartsen and S. Agland and J. Baker and T. Burke and L. Rath and J. Lechner-Scott and B. Taylor and S. Vucic and M. Barnett and M. Slee and S. Hodgkinson and O. Skibina and A. Kermode and E. Butler and N. Shuey and C. Shaw and T. Hardy and Tan, {I. L.} and H. Butzkueven and T. Spelman",

year = "2015",

language = "English",

volume = "21",

pages = "18--19",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

}

Haartsen, J, Agland, S, Baker, J, Burke, T, Rath, L, Lechner-Scott, J, Taylor, B, Vucic, S, Barnett, M, Slee, M, Hodgkinson, S, Skibina, O, Kermode, A, Butler, E, Shuey, N, Shaw, C, Hardy, T, Tan, IL, Butzkueven, H & Spelman, T 2015, 'MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events', Multiple Sclerosis Journal, vol. 21, pp. 18-19.

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events. / Haartsen, J.; Agland, S.; Baker, J. et al.

In: Multiple Sclerosis Journal, Vol. 21, 2015, p. 18-19.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

AU - Haartsen, J.

AU - Agland, S.

AU - Baker, J.

AU - Burke, T.

AU - Rath, L.

AU - Lechner-Scott, J.

AU - Taylor, B.

AU - Vucic, S.

AU - Barnett, M.

AU - Slee, M.

AU - Hodgkinson, S.

AU - Skibina, O.

AU - Kermode, A.

AU - Butler, E.

AU - Shuey, N.

AU - Shaw, C.

AU - Hardy, T.

AU - Tan, I. L.

AU - Butzkueven, H.

AU - Spelman, T.

PY - 2015

Y1 - 2015

UR - https://publons.com/publon/4889986/

M3 - Abstract/Meeting Abstract

VL - 21

SP - 18

EP - 19

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

Other files and links

Cite this